NLRP3 and pulmonary fibrosis: On the contrary, currently used chemotherapeutics activate the NLRP3 inflammasome at differential extent in a more unspecific manner and thereby may cause side effects such as cardiotoxicity (anthracyclines) [25], intestinal mucositis (5-fluoruracil) [46], or pulmonary fibrosis (bleomycin) [47].